Partner With Us NRI

Laurus Labs Ltd share Price Today

Company details

6M Return 14.15%
1Y Return 27.85%
Mkt Cap.(Cr) 23,059.66
Volume 1,157,636
Div Yield 0.09%
OI Chg %
Volume 1,157,636

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Slowdown in custom synthesis weighs on numbers..
About The Stock

    Laurus Labs operates in the segment of generic APIs & FDFs (formulations), custom synthesis and biotechnology. Major focus in APIs is on ARV, oncology and other APIs.

    • It owns 11 manufacturing units (six FDA approved sites) with 74 DMFs, 32 ANDAs filed (15 Para IV, 11 first to file) and 192 patents granted.

    • Laurus acquired Richore Life Sciences to diversify in recombinant animal origin free products, enzymes as well as building biologics custom synthesis.


    Mixed set of numbers with a sharp fall in margins.

    • Revenues were in line, down 3.1% YoY at ₹ 1,381 crore

    • EBITDA de-grew 28% YoY to ~₹ 286 crore while EBITDA margins corrected ~716 bps YoY to 20.7%. PAT came in at ₹ 105.3 crore for the quarter

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Laurus Labs announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue at Rs 1,440 crore, 4 % (YoY)
  • EBITDA at Rs 259 crore, -10 % (YoY)
  • EBITDA margins at 18.0 %
  • Spend on New Initiatives (Cell & Gene Therapy, Animal Health) at Rs 12 crore
  • PAT at Rs 76 crore, -26% (YoY)
  • PAT margins at 5.2%
  • EPS (Diluted) for the period at Rs 1.4 per share (not annualised)
  • Interim Dividend of Rs 0.40/- per share

FY24 Financial Highlights:

  • Revenue at Rs 5,041 crore, -17% (YoY) Excluding the large PO, growth of 9%
  • EBITDA at Rs 798 crore, -50 % (YoY)
  • EBITDA margins at 15.8 %
  • Spend on New Initiatives (Cell & Gene Therapy, Animal Health) at Rs 50 crore
  • PAT at Rs 161 crore, -80% (YoY)
  • PAT margins at 3.2%
  • EPS (Diluted) for the period at Rs 2.9 per share 

Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated “Laurus core results reflects continued resilience across our business divisions despite discontinuation of Covid related products purchase orders. We delivered underlying revenue growth of 9% driven by strong performance in FDF, CDMO, Onco API and Bio division. In the CDMO space, we are delivering on multiple RFPs involving higher chemical complexity and scale with increased customer engagement focusing on several sustainable technology platforms. Our on-going innovative CGT investment continue to report significant updates for the period under review, especially successful NexCAR19 commercial launch in India to treat cancers. We are entering FY25 with solid foundation and remain committed to grow by focusing on R&D led commercial excellence. We are prioritizing efforts to improve margin, particularly increasing asset utilization across network and delivering late phase commercial opportunity. At the same time, we have been investing in Laurus future and continuing to create value for all stakeholders.” 

Commenting on the results, V V Ravi Kumar, Executive Director & Chief Financial Officer said, “Overall FY24 reported operating result was challenging driven by selling price decline in ARV products, absence of large PO, and continued OPEX on growth projects/new initiatives. We achieved Rs 5,041 crore in revenues, representing 17% decline. Excluding the large PO the underlying growth was 9% over last year. Gross margin was 51.7% and EBITDA at Rs 798 crore resulting in 15.8% margin. The EBIDTA margin for the Q4FY24 is at 18.0% and reflecting sequential improvement. Despite operational challenges, our committed capacity built-up is on track and continuing our focus on productivity improvement. Going ahead, we are fully focusing on gradually returning to growth, prioritising investments in high value segments, improving Net debt leverage while defining our strategic roadmap to ensure long-term profitable and sustainable growth. We are pleased with our Q4 sequential improvement, supported from all divisions."

Result PDF

View Other Company Results

Laurus Labs Ltd shares SWOT Analysis

Strengths (4)

  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Book Value per share Improving for last 2 years
  • Company with Zero Promoter Pledge

Weakness (7)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (1)

  • Negative to Positive growth in Sales and Profit with Strong Price momentum

Threats (3)

  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income
  • RSI indicating price weakness

Resistance and support

R1 437.3
R2 446.8
R3 452.5


S1 422.1
S2 416.4
S3 406.9
Delivery and volume
ARUN VIJAY NATHANI Block Purchase 2023-03-14 305 635894 NSE
CYBAGE SOFTWARE PRIVATE LIMITED Block Sell 2023-03-14 305 635894 NSE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-11-14 455.4 529337 NSE
Name Category Shares
M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava) PROMOTER 23.03%
M/s. Leven Holdings (Represented by its Managing Partner, Mr. Venkata Ravi Kumar Vantaram) PROMOTER 1.24%


Investment recommendation
Slowdown in custom synthesis weighs on numbers..
Call Date
28 Apr 2023
Entry Price 292.00
Target Price 300.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Laurus Labs Ltd Stocks COMPARISON

Financials( in Cr) Laurus Labs Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 427.85 1,459.10 1,466.60 4,412.80 1,023.95
% Change -2.87 -1.34 -1.80 -0.79 -1.99
Mcap Cr 23,059.66 350,086.97 118,408.44 117,146.16 103,033.33
Revenue TTM Cr 6,040.55 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 796.64 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 143.32 34.99 27.77 73.21 26.72
1 Year Return 27.85 50.66 53.37 26.88 99.97
ROCE 21.78 16.79 14.76 19.30 16.25
ROE 21.56 16.46 10.66 14.89 14.05

Equity Capital: 4,037.53 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 39,641.00 -26,315.30
LAST 3M 112,356.80 -35,490.78
LAST 6M 175,524.06 28,431.26
LAST 12M 275,282.89 115,769.27
Laurus Labs Limited - ESOP/ESOS/ESPS

May 28, 2024 l NSE Announcement

Laurus Labs allots 1.93 lakh equity shares under ESOS

May 28, 2024 l BSE Announcement

Date Action Type Ratio
May 08, 2024 Dividend 20
Nov 02, 2023 Dividend 20
May 10, 2023 Dividend 60

Laurus Labs Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Laurus Labs Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 37508.48 crores, it is incorporated in the year 2005. It features consolidated sales of Rs. 1220.60 crores in June 2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 540222 and additionally listed in the National Stock Exchange (NSE) with the code LAURUSLABS.

    Laurus Labs is one of the top pharmaceuticals companies in the country, holding a leadership position in research & development and manufacturing of generic APIs. The company is also working with several top pharmaceuticals companies worldwide for research & development with a primary focus on anti-retroviral, Hepatitis C, and Oncology drugs. The company also owns around 155 patents. The headquarters of Laurus labs are situated in the city of Hyderabad, while its manufacturing plants are located in Visakhapatnam, Hyderabad, and Bengaluru. Laurus Labs has also received several approvals from major regulatory medical bodies worldwide, such as WHO, USFDA, KFDA, MHRA, etc. In March’20, Laurus Labs received approval from USFDA for hydroxychloroquine tablets, which were initially used to treat the COVID-19 patients. The promoters within the company currently hold 53.56% of the stake in the company, while the Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) hold 6.65% and 3.44% of the stake. The balance of 36.35% is by others (retail investors).

    In June 2021, quarterly net sales were Rs. 1,220.6 crores, which has increased by approximately 25.78% from Rs. 970.4 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 222.08 crores, which has grown by 39.87% from a net profit of Rs. 158.78 crores in June 2020. In June 2021, operating profit was reported at Rs. 1,032.11 crores, which is also increased by 25.79% as compared to an operating profit of Rs. 820.49 crores for the quarter ending in June 2020. From Rs. 2.97 in June 2020, the EPS of Laurus Labs has grown to just Rs. 4.14 per share in June 2021. LAURUSLABS’s stock closed at Rs. 689.35 on 16th August’2021 (NSE) and has returned 86.97% in the last six months and 234.49% within the last year.

Registered Address

Plot No 21 Jawaharlal Nehru, Pharma City Parawada, Visakhapatnam, Andhra Pradesh, 531021

Tel : 91-891-3061222
Email : secretarial:lauruslabs.com; info:lauruslabs.com
Website : http://www.lauruslabs.com

KFin Techologies Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 540222
Book Closure Date (Month) : Jul
BSE Group : A
ISIN : INE947Q01028

FAQ’s on Laurus Labs Ltd Shares

You can buy Laurus Labs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Laurus Labs Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 30, 2024 03:59 PM the closing price of Laurus Labs Ltd was Rs.427.85.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 30, 2024 03:59 PM, the market cap of Laurus Labs Ltd stood at Rs. 23,059.66.

The latest PE ratio of Laurus Labs Ltd as of May 30, 2024 03:59 PM is 143.32

The latest PB ratio of Laurus Labs Ltd as of May 30, 2024 03:59 PM is 0.18

The 52-week high of Laurus Labs Ltd share price is Rs. 471.00 while the 52-week low is Rs. 325.30

According to analyst recommendations, Laurus Labs Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app